Report of Foreign Issuer (6-k)
19 Febrero 2020 - 8:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February, 2020
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrant’s name into English)
4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Exhibit Index
|
|
|
|
|
Exhibit
No.
|
|
Exhibit
|
|
|
|
|
10.1
|
|
Securities Purchase Agreement, dated February 19, 2020, by and between Mereo BioPharma Group PLC and Boxer Capital, LLC
|
|
|
|
|
10.2
|
|
Registration Rights Agreement, dated February 19, 2020, by and between Mereo BioPharma Group PLC and Boxer Capital, LLC
|
|
|
|
|
99.1
|
|
Press release dated February 19, 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: February 19, 2020
|
|
|
|
|
MEREO BIOPHARMA GROUP PLC
|
|
|
|
|
By:
|
|
/s/ Denise Scots-Knight, Ph.D.
|
|
|
|
Name: Denise Scots-Knight, Ph.D.
|
|
|
|
Title: Chief Executive Officer
|
Mereo BioPharma (NASDAQ:MREO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Mereo BioPharma (NASDAQ:MREO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
